Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Krystal Biotech Inc (NQ: KRYS )

74.23 +1.84 (+2.54%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 23, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 130,345
Open 73.29
Bid (Size) 74.04 (4)
Ask (Size) 74.23 (4)
Prev. Close 72.39
Today's Range 72.93 - 75.61
52wk Range 47.67 - 89.59
Shares Outstanding 22,205,642
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Expert Ratings for Krystal Biotech
 
Via Benzinga
Dentsply Sirona, Chico's FAS, Kontoor Brands And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded lower, with the Dow Jones dropping more than 150 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga

Performance

YTD
-6.31%
-6.31%
1 Month
-4.29%
-4.29%
3 Month
-4.16%
-4.16%
6 Month
+7.18%
+7.18%
1 Year
+9.84%
+9.84%

More News

Read More
Benzinga's Top Ratings Upgrades, Downgrades For February 28, 2023
Via Benzinga
Krystal Biotech Epidermolysis Bullosa Study Data Published In New England Journal Of Medicine
Via Benzinga
2 Risky Stocks That Could Soar in 2023
Via The Motley Fool
Krystal Biotech's Subsidiary Posts Durability Data For Fine Line, Wrinkles
Via Benzinga
Recap: Krystal Biotech Q3 Earnings
Via Benzinga
Have A Look At William Blair's Top Biotech Picks For 2023
Via Benzinga
The 7 Hottest Biotech Stocks to Own in 2023 and Beyond
Via InvestorPlace
SolarEdge To Rally 54%? Plus This Analyst Predicts $1,335 For Mettler-Toledo International
Via Benzinga
Cigna To $335? Plus This Analyst Slashes PT On Six Flags Entertainment By 25%
Via Benzinga
Recap: Krystal Biotech Q4 Earnings
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 25, 2022
Via Benzinga
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
FDA Accepts Krystal Biotech's Filing For Genetic Skin Disorder Candidate Under Priority Review
Via Benzinga
Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study
Via Benzinga
Recap Of Monday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Krystal Biotech Gets FDA Nod For Initial-Stage Lung Infection Study
Via Benzinga
Krystal Biotech Files To Seek Approval For Skin Disease Candidate
Via Benzinga
The Daily Biotech Pulse: Precision BioSciences Inks Gene Editing Pact, Athira Pharma's Alzheimer's Candidate Fails, Enanta Sues Pfizer Over COVID-19 Antiviral
Via Benzinga
The Daily Biotech Pulse: Thumbs Down For Acadia's Pimavanserin, Pfizer Buys Stake In Valneva, AstraZeneca - Ionis Eplontersen Aces Rare Disease Trial
Via Benzinga
Krystal Biotech Stock Sees Healthy Relative Strength Rating Upgrade
Via Investor's Business Daily
BofA Bullish On This Gene Therapy Biotech Transitioning Into A Commercial Enterprise
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 18, 2022
Via Benzinga
Why Krystal Biotech's Shares Rose More Than 77% This Week
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.